U.S. Venture Partners

U.S. Venture Partners (USVP), founded in 1981 and based in Menlo Park, California, is a venture capital firm that specializes in early-stage investments. The firm focuses on transformative ideas within the information technology and healthcare sectors, emphasizing innovation that drives economic growth and job creation. USVP's investment areas include enterprise software, IT security, consumer internet, mobile applications, e-commerce, healthcare, and IT-enabled healthcare services. The team at USVP comprises former entrepreneurs, technologists, corporate executives, financial professionals, and industry experts, all dedicated to supporting entrepreneurs in their journey to build impactful companies. The firm primarily targets businesses located on the West Coast of the United States, seeking opportunities in B2B, life sciences, oncology, cybersecurity, digital health, and cloud technology.

Jacques Benkoski

General Partner

Dale Holladay

CFO

Steven Krausz

General Partner

Rick Lewis

General Partner

Jonathan Root

General Partner

Casey Tansey

General Partner

Past deals in Oregon

HeartFlow

Convertible Note in 2025
HeartFlow, Inc. is a medical technology company that specializes in non-invasive solutions for coronary artery disease detection. Founded in 2007 and based in Redwood City, California, with additional offices in Portland, Austin, London, and Tokyo, the company offers its HeartFlow Analysis, which utilizes data from standard computerized tomography scans to create personalized three-dimensional models of a patient's heart. This analysis helps clinicians evaluate the impact of blockages on blood flow, facilitating informed treatment decisions while minimizing the need for invasive testing. HeartFlow's technology integrates over two decades of scientific research with advancements in artificial intelligence, making its HeartFlow FFRCT Analysis available in the United States, Canada, Europe, the United Kingdom, and Japan.

Sparrow Pharmaceuticals

Venture Round in 2024
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for disorders related to corticosteroid excess. Founded in 2013 by David A. Katz and based in Portland, Oregon, the company aims to provide better therapeutic options for patients suffering from hypercortisolism and autoimmune or inflammatory conditions. By utilizing unique insights into corticosteroid biology, Sparrow is advancing its lead product, SPI-62, an oral small molecule treatment that specifically targets the source of active intracellular corticosteroids in critical tissues. This approach is designed to alleviate the adverse effects of both naturally occurring corticosteroids, such as cortisol due to tumors, and the long-term use of corticosteroid medications like prednisone.

HeartFlow

Series F in 2023
HeartFlow, Inc. is a medical technology company that specializes in non-invasive solutions for coronary artery disease detection. Founded in 2007 and based in Redwood City, California, with additional offices in Portland, Austin, London, and Tokyo, the company offers its HeartFlow Analysis, which utilizes data from standard computerized tomography scans to create personalized three-dimensional models of a patient's heart. This analysis helps clinicians evaluate the impact of blockages on blood flow, facilitating informed treatment decisions while minimizing the need for invasive testing. HeartFlow's technology integrates over two decades of scientific research with advancements in artificial intelligence, making its HeartFlow FFRCT Analysis available in the United States, Canada, Europe, the United Kingdom, and Japan.

Sparrow Pharmaceuticals

Series A in 2021
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for disorders related to corticosteroid excess. Founded in 2013 by David A. Katz and based in Portland, Oregon, the company aims to provide better therapeutic options for patients suffering from hypercortisolism and autoimmune or inflammatory conditions. By utilizing unique insights into corticosteroid biology, Sparrow is advancing its lead product, SPI-62, an oral small molecule treatment that specifically targets the source of active intracellular corticosteroids in critical tissues. This approach is designed to alleviate the adverse effects of both naturally occurring corticosteroids, such as cortisol due to tumors, and the long-term use of corticosteroid medications like prednisone.

Act-On Software

Venture Round in 2021
Act-On Software, Inc. is a developer of a cloud-based marketing automation platform tailored for small and mid-sized businesses. The platform enables marketers to create and manage various marketing campaigns, including email marketing, website lead generation, social media marketing, and account-based marketing. Act-On's solutions help organizations attract prospects, convert leads, and measure campaign effectiveness while enhancing customer engagement and brand awareness. Additionally, the company offers professional consulting, support, and training services to optimize the use of its platform. Act-On serves diverse industries such as banking, insurance, manufacturing, technology, and agencies. Founded in 2006 and headquartered in Portland, Oregon, Act-On also has locations in Scottsdale, Arizona, and Reading, United Kingdom.

Act-On Software

Venture Round in 2014
Act-On Software, Inc. is a developer of a cloud-based marketing automation platform tailored for small and mid-sized businesses. The platform enables marketers to create and manage various marketing campaigns, including email marketing, website lead generation, social media marketing, and account-based marketing. Act-On's solutions help organizations attract prospects, convert leads, and measure campaign effectiveness while enhancing customer engagement and brand awareness. Additionally, the company offers professional consulting, support, and training services to optimize the use of its platform. Act-On serves diverse industries such as banking, insurance, manufacturing, technology, and agencies. Founded in 2006 and headquartered in Portland, Oregon, Act-On also has locations in Scottsdale, Arizona, and Reading, United Kingdom.

Act-On Software

Series D in 2012
Act-On Software, Inc. is a developer of a cloud-based marketing automation platform tailored for small and mid-sized businesses. The platform enables marketers to create and manage various marketing campaigns, including email marketing, website lead generation, social media marketing, and account-based marketing. Act-On's solutions help organizations attract prospects, convert leads, and measure campaign effectiveness while enhancing customer engagement and brand awareness. Additionally, the company offers professional consulting, support, and training services to optimize the use of its platform. Act-On serves diverse industries such as banking, insurance, manufacturing, technology, and agencies. Founded in 2006 and headquartered in Portland, Oregon, Act-On also has locations in Scottsdale, Arizona, and Reading, United Kingdom.

Act-On Software

Series C in 2011
Act-On Software, Inc. is a developer of a cloud-based marketing automation platform tailored for small and mid-sized businesses. The platform enables marketers to create and manage various marketing campaigns, including email marketing, website lead generation, social media marketing, and account-based marketing. Act-On's solutions help organizations attract prospects, convert leads, and measure campaign effectiveness while enhancing customer engagement and brand awareness. Additionally, the company offers professional consulting, support, and training services to optimize the use of its platform. Act-On serves diverse industries such as banking, insurance, manufacturing, technology, and agencies. Founded in 2006 and headquartered in Portland, Oregon, Act-On also has locations in Scottsdale, Arizona, and Reading, United Kingdom.

Act-On Software

Series B in 2010
Act-On Software, Inc. is a developer of a cloud-based marketing automation platform tailored for small and mid-sized businesses. The platform enables marketers to create and manage various marketing campaigns, including email marketing, website lead generation, social media marketing, and account-based marketing. Act-On's solutions help organizations attract prospects, convert leads, and measure campaign effectiveness while enhancing customer engagement and brand awareness. Additionally, the company offers professional consulting, support, and training services to optimize the use of its platform. Act-On serves diverse industries such as banking, insurance, manufacturing, technology, and agencies. Founded in 2006 and headquartered in Portland, Oregon, Act-On also has locations in Scottsdale, Arizona, and Reading, United Kingdom.

Act-On Software

Venture Round in 2010
Act-On Software, Inc. is a developer of a cloud-based marketing automation platform tailored for small and mid-sized businesses. The platform enables marketers to create and manage various marketing campaigns, including email marketing, website lead generation, social media marketing, and account-based marketing. Act-On's solutions help organizations attract prospects, convert leads, and measure campaign effectiveness while enhancing customer engagement and brand awareness. Additionally, the company offers professional consulting, support, and training services to optimize the use of its platform. Act-On serves diverse industries such as banking, insurance, manufacturing, technology, and agencies. Founded in 2006 and headquartered in Portland, Oregon, Act-On also has locations in Scottsdale, Arizona, and Reading, United Kingdom.

HeartFlow

Seed Round in 2008
HeartFlow, Inc. is a medical technology company that specializes in non-invasive solutions for coronary artery disease detection. Founded in 2007 and based in Redwood City, California, with additional offices in Portland, Austin, London, and Tokyo, the company offers its HeartFlow Analysis, which utilizes data from standard computerized tomography scans to create personalized three-dimensional models of a patient's heart. This analysis helps clinicians evaluate the impact of blockages on blood flow, facilitating informed treatment decisions while minimizing the need for invasive testing. HeartFlow's technology integrates over two decades of scientific research with advancements in artificial intelligence, making its HeartFlow FFRCT Analysis available in the United States, Canada, Europe, the United Kingdom, and Japan.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.